At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09887 LEADS BIOLABS-B
Closed 07-02 16:08:21
51.050
+1.730
+3.51%
High53.100Low49.580Vol573.50K
Open50.500D1 Closing49.320Amplitude7.14%
Mkt Cap10.16BTradable Cap10.11BTotal Shares199.00M
T/O29.41MT/O Rate0.29%Tradable Shares198.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Leads Biolabs Converts 44.39 Million Unlisted Shares to H Shares, Lifting Outstanding H Shares to 197.67 Million
Bulletin Express  ·  17:25
Leads Biolabs Converts 44.39 Million Unlisted Shares to H Shares, Lifting Outstanding H Shares to 197.67 Million
LEADS BIOLABS-B Awards 2.2547 Million Shares Under H-Share Incentive Scheme
Stock News  ·  07-01 20:20
LEADS BIOLABS-B Awards 2.2547 Million Shares Under H-Share Incentive Scheme
Nanjing Leads Biolabs Grants 2,254,691 H-share Awards Under Employee Incentive Scheme
Reuters  ·  07-01 19:45
Nanjing Leads Biolabs Grants 2,254,691 H-share Awards Under Employee Incentive Scheme
This Nanjing Leads Biolabs Insider Reduced Their Stake By 40%
Simply Wall St.  ·  06-30 09:44
This Nanjing Leads Biolabs Insider Reduced Their Stake By 40%
Assessing LEADS BIOLABS-B After a 50% Price Drop: H-Share Full Circulation, Early Shareholder Unlock, and Custody Movements
Stock News  ·  06-26
Assessing LEADS BIOLABS-B After a 50% Price Drop: H-Share Full Circulation, Early Shareholder Unlock, and Custody Movements
New Energy System Blueprint and Rural EV Initiative Unveiled as Key Stocks Report Earnings
Stock News  ·  06-26
New Energy System Blueprint and Rural EV Initiative Unveiled as Key Stocks Report Earnings
Leads Biolabs Announces Partner Oblenio Bio’s $62 Million Oversubscribed Series B Financing to Advance Tri-specific T-cell Engager Lbl‑051 for Autoimmune Diseases into Clinical Development
THOMSON REUTERS  ·  06-25
Leads Biolabs Announces Partner Oblenio Bio’s $62 Million Oversubscribed Series B Financing to Advance Tri-specific T-cell Engager Lbl‑051 for Autoimmune Diseases into Clinical Development
Nanjing Leads Biolabs Co - Series B Round Led by Pfizer Ventures with Deep Track Capital, Gv, and Aditum Bio
THOMSON REUTERS  ·  06-25
Nanjing Leads Biolabs Co - Series B Round Led by Pfizer Ventures with Deep Track Capital, Gv, and Aditum Bio
Nanjing Leads Biolabs Says Partner Oblenio Moves Lbl-051 Toward Clinical Trial Start After US$62 Million Series B Financing
Reuters  ·  06-25
Nanjing Leads Biolabs Says Partner Oblenio Moves Lbl-051 Toward Clinical Trial Start After US$62 Million Series B Financing
Leads Biolabs Completes H-Share Full Circulation, Free-Float Rises to 99.39%
Bulletin Express  ·  06-05
Leads Biolabs Completes H-Share Full Circulation, Free-Float Rises to 99.39%
Nanjing Leads Biolabs converts 44,391,598 unlisted shares into H shares for HKEX listing
Reuters  ·  06-05
Nanjing Leads Biolabs converts 44,391,598 unlisted shares into H shares for HKEX listing
LEADS BIOLABS-B Records HK$1.486 Billion in Deposited Shares as Major Holder Transfers 25.85 Million Shares
Stock News  ·  06-05
LEADS BIOLABS-B Records HK$1.486 Billion in Deposited Shares as Major Holder Transfers 25.85 Million Shares
Nanjing Leads Biolabs says LBL-024 Phase II first-line NSCLC data wins oral slot at 2026 WCLC
Reuters  ·  05-28
Nanjing Leads Biolabs says LBL-024 Phase II first-line NSCLC data wins oral slot at 2026 WCLC
Leads Biolabs to Spend up to US$50 Million on Trustee-Led H-Share Purchases for Employee Award Scheme
Bulletin Express  ·  05-20
Leads Biolabs to Spend up to US$50 Million on Trustee-Led H-Share Purchases for Employee Award Scheme
LEADS BIOLABS-B (09887) Authorizes Trustee to Acquire Up to $50 Million Worth of H Shares Under Incentive Plan
Stock News  ·  05-20
LEADS BIOLABS-B (09887) Authorizes Trustee to Acquire Up to $50 Million Worth of H Shares Under Incentive Plan
Nanjing Leads Biolabs Co Ltd - Instructs Trustee to Buy H Shares up to US$50 Mln Under H Share Award Scheme
THOMSON REUTERS  ·  05-20
Nanjing Leads Biolabs Co Ltd - Instructs Trustee to Buy H Shares up to US$50 Mln Under H Share Award Scheme
LEADS BIOLABS-B Surges Over 4% in Morning Trading Following Phase III Clinical Trial Approval for Velishen™
Stock News  ·  05-19
LEADS BIOLABS-B Surges Over 4% in Morning Trading Following Phase III Clinical Trial Approval for Velishen™
Leads Biolabs Gains CDE Green Light for Phase III Trial of PD-L1/4-1BB Bispecific Antibody in First-Line EP-NEC
Bulletin Express  ·  05-19
Leads Biolabs Gains CDE Green Light for Phase III Trial of PD-L1/4-1BB Bispecific Antibody in First-Line EP-NEC
LEADS BIOLABS-B (09887): Phase 3 Trial for VELIXIN™ (PD-L1/4-1BB Bispecific Antibody Opatumilab) in Advanced Extrapulmonary Neuroendocrine Carcinoma Receives CDE Approval
Stock News  ·  05-19
LEADS BIOLABS-B (09887): Phase 3 Trial for VELIXIN™ (PD-L1/4-1BB Bispecific Antibody Opatumilab) in Advanced Extrapulmonary Neuroendocrine Carcinoma Receives CDE Approval
Nanjing Leads Biolabs wins China CDE clearance for LBL-024 Phase III EP-NEC trial
Reuters  ·  05-19
Nanjing Leads Biolabs wins China CDE clearance for LBL-024 Phase III EP-NEC trial

Introduction

Company Name.
LEADS BIOLABS-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Nanjing Leads Biolabs Co Ltd is a China-based company primarily engaged in the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. The Company’s main drug candidates include LBL-024, LBL-034, LBL-033, LBL-007 and others. The company's LBL-024 is mainly used to treat extra-pulmonary neuroendocrine carcinoma (EP-NEC), small cell lung cancer (SCLC), biliary tract carcinoma (BTC), non-small-cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), gastric cancer (GC) and other solid tumors. The Company has also developed multiple proprietary technology platforms, including LeadsBod platform (a CD3 T-cell engager platform), X-body platform (a 4-1BB engager platform) and several other bispecific antibody and fusion protein platforms. The Company mainly conducts its business in the domestic market.
Issue price:
--